Structure-Activity Relationships and Pharmacokinetics of
GLP-1R
SAR
albumin binder
exendin-4
insulinoma
Journal
Molecular pharmaceutics
ISSN: 1543-8392
Titre abrégé: Mol Pharm
Pays: United States
ID NLM: 101197791
Informations de publication
Date de publication:
01 08 2022
01 08 2022
Historique:
pubmed:
28
6
2022
medline:
3
8
2022
entrez:
27
6
2022
Statut:
ppublish
Résumé
Insulinomas are neuroendocrine tumors that are derived from pancreatic β-cells, and they often overexpress the glucagon-like peptide-1 receptor (GLP-1R). Radiolabeled exendin-4 derivatives have been used to noninvasively detect the GLP-1R during the diagnosis and preoperative localization of insulinomas; however, their marked renal accumulation can hinder the imaging of pancreatic tail lesions. In this study, we designed and synthesized
Identifiants
pubmed: 35757958
doi: 10.1021/acs.molpharmaceut.2c00201
doi:
Substances chimiques
Albumins
0
Glucagon-Like Peptide-1 Receptor
0
Peptides
0
Indium
045A6V3VFX
Exenatide
9P1872D4OL
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM